

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4962978

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
JIAN LIN	02/15/2018
ANNA ERICSSON	02/15/2018
ANN-MARIE CAMPBELL	02/27/2018
GARY GUSTAFSON	05/08/2018
ZHONGGUO WANG	02/14/2018
R. BRUCE DIEBOLD	02/15/2018
SUSAN ASHWELL	02/15/2018
DAVID R. LANCIA JR.	02/15/2018
JUSTIN ANDREW CARAVELLA	04/13/2018
WEI LU	03/09/2018
RECEIVING PARTY DATA	
Name:	FORMA THERAPEUTICS, INC.
Street Address:	500 ARSENAL STREET
Internal Address:	SUITE 100
City:	WATERTOWN
State/Country:	MASSACHUSETTS
Postal Code:	02472
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15568051
CORRESPONDENCE DATA	
Fax Number:	(617)502-5002
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	617-248-5000
Email:	PatentDocket@choate.com
Correspondent Name:	CHOATE HALL & STEWART LLP-PATENT DOCKET
Address Line 1:	TWO INTERNATIONAL PLACE
Address Line 4:	BOSTON, MASSACHUSETTS 02110

ATTORNEY DOCKET NUMBER:	2012552-0597
NAME OF SUBMITTER:	JOHN P. REARICK
SIGNATURE:	/John P. Rearick/
DATE SIGNED:	05/15/2018

Total Attachments: 15

source=2012552_0597_Assignment#page1.tif
 source=2012552_0597_Assignment#page2.tif
 source=2012552_0597_Assignment#page3.tif
 source=2012552_0597_Assignment#page4.tif
 source=2012552_0597_Assignment#page5.tif
 source=2012552_0597_Assignment#page6.tif
 source=2012552_0597_Assignment#page7.tif
 source=2012552_0597_Assignment#page8.tif
 source=2012552_0597_Assignment#page9.tif
 source=2012552_0597_Assignment#page10.tif
 source=2012552_0597_Assignment#page11.tif
 source=2012552_0597_Assignment#page12.tif
 source=2012552_0597_Assignment#page13.tif
 source=2012552_0597_Assignment#page14.tif
 source=2012552_0597_Assignment#page15.tif

COMBINED JOINT ASSIGNMENT & DECLARATION**A. ASSIGNMENT**

WHEREAS, each of the below-named inventors whose name and residence is set forth in the following Table 1:

Inventor Name	City, State
1. Jian Lin	Acton, Massachusetts
2. Anna Ericsson	Shrewsbury, Massachusetts
3. Ann-Marie Campbell	Monroe, Connecticut
4. Gary Gustafson	Ridgefield, Connecticut
5. Zhongguo Wang	Lexington, Massachusetts
6. R. Bruce Diebold	Waltham, Massachusetts
7. Susan Ashwell	Carlisle, Massachusetts
8. David R. Lancia, Jr.	Boston, Massachusetts
9. Justin Andrew Caravella	Cambridge, Massachusetts
10. Wei Lu	Newton, Massachusetts

Table 1

hereby declares and agrees, on behalf of himself/herself and all of his/her successors and assigns that each is aware of the patent application(s) entitled:

**FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-
ISOCITRATE DEHYDROGENASE INHIBITORS; and**

☒ identified by United States Application Serial No. 15/568,051
filed in the United States Patent and Trademark Office on; October 20, 2017; and

☒ identified by International Patent Application No. PCT/US2015/051056
filed on September 18, 2015; and

☒ and is also aware of the following priority applications:

Serial No.	Filed
62/150815	April 21, 2015

WHEREAS **FORMA Therapeutics, Inc.** (hereinafter "ASSIGNEE"), having a usual place of business at **500 Arsenal Street, Suite 100, Watertown, MA 02472**, desires to acquire or confirm an interest therein;

NOW, THEREFORE, to all whom it may concern be it known that, in consideration of agreements previously and duly entered into between the parties, and/or for other good and valuable consideration, the receipt of which is hereby acknowledged, each of us has sold, assigned, and transferred and/or do hereby sell, assign, and transfer unto said ASSIGNEE, its successors, assigns, and legal representatives, my entire right, title, and interest in and throughout the United States of America, its territories and all foreign countries, in and to any and all inventions described in the patent application, and/or any priority applications noted above, including any right of priority thereto; and hereby confirm that my sale, assignment and transfer is and was effective at least as of the filing date of the patent application and/or priority application. Our sale, assignment and transfer applies to the above-referenced patent application, and to any application that is based in whole or in part on the patent application, including any divisional, continuing, substitute, renewal, reissue, reexamination and other applications, for example that claim priority to the patent application. Also, this sale, assignment and transfer pertains to any and all other rights arising under or pursuant to any and all international agreements, treaties, or laws relating to the protection of industrial property, including all rights of priority under the International Convention for the Protection of Industrial Property, and in and to any such patent(s) as may issue thereon including any and all original and reissued patents which have been or shall be issued in the United States and foreign countries; said inventions, applications, and patent(s) to be held and enjoyed by ASSIGNEE for its own use and for its successors, assigns and legal representatives, to the full end of the term for which said patent(s) may be granted as fully and entirely as the same would have been held by each of us had this sale, assignment and transfer not been made;

AND, each of us hereby acknowledges that this Assignment, being of our entire right, title, and interest in and to the inventions, carries with it the right in ASSIGNEE, by attorneys and agents of ASSIGNEE selection, to apply for and receive any and all patent(s) for said inventions in its own name;

AND, each of us hereby further agrees for ourselves and our executors and administrators to execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the patent(s) to ASSIGNEE, its successors, assignees, and legal representatives, but at its expense and charges, including the execution of application for patents in foreign countries, the execution of substitution, reissue, divisional or continuation applications, and the giving of testimony, preliminary statements, or other statements in any interference or other proceeding in which the inventions or any applications or patents directed to the inventions may be involved by communicating to the ASSIGNEE all facts we know relating to the inventions and their history, and generally by doing everything possible which ASSIGNEE shall consider desirable for aiding in securing and maintaining proper patent protection for the inventions and for vesting title in the inventions and all applications for patent and all patents on the inventions in ASSIGNEE;

AND, each of us further hereby authorizes ASSIGNEE or its attorneys or agents to insert the correct serial number(s) and/or filing date(s) into this assignment document, if appropriate;

AND, each of us hereby appoints ASSIGNEE as our common agent for purposes of prosecuting international patent applications and any national patent applications for which such common agency is recognized;

AND, each of us hereby requests the Commissioner for Patents of the United States Patent and Trademark Office to issue any and all patent(s) as shall be granted upon said application or applications based thereon to ASSIGNEE, its successors, assigns, and legal representatives;

AND, each of us covenants with said ASSIGNEE that no assignment, grant, mortgage, license, or other agreement affecting the rights and property herein conveyed has been made to others by us, and that full right to convey the same as herein expressed is possessed by us.

B. DECLARATION (37 CFR 1.63)

As below named inventors, we hereby declare that:

This declaration is directed to the patent application entitled:

**FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-
ISOCITRATE DEHYDROGENASE INHIBITORS;** and

☒ identified by United States Application Serial No. 15/568,051
filed in the United States Patent and Trademark Office on October 20, 2017; or

☒ identified by International Patent Application No. PCT/US2015/051056
filed on September 18, 2015.

The above-identified application was made or authorized to be made by us.

We believe that we are each an original joint inventor of a claimed invention in the application.

We hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

We have reviewed and understand the contents of the application, including the claims and are aware of the duty to disclose to the United States Patent and Trademark Office all information known to be material to patentability as defined in 37 CFR 1.56.

Signature:

Jian Lin

Date:

02/15/2018

Witness Signature:

Z. G. Wang

Date:

02/15/2018

Witness Name (printed):

Zhongguo Wang

Witness Signature:


Fabrizio Venancio

Date:

2/15/2018

Witness Name (printed):

Fabrizio Venancio

Signature: 
Anna Ericsson

Date: 02 15 18

Witness Signature: 
Witness Name (printed): David R. Lancia Jr.

Date: 2/15/2018

Witness Signature: 
Witness Name (printed): FABRICIO VENANCIO

Date: 2/15/2018

Signature: Ann-Marie Campbell
Ann-Marie Campbell

Date: 02-27-2018

Witness Signature: M. Z...

Date: 2/27/2018

Witness Name (printed): ADAM TALBOT

Witness Signature: Kyle Bassoli

Date: 2/27/2018

Witness Name (printed): Kyle Bassoli

Signature: _____

Gary Gustafson

Date: _____

5/8/18

Witness Signature: _____

Derek Gustafson

Date: _____

5/8/18

Witness Name (printed): _____

Derek Gustafson

Witness Signature: _____

Darlene Gustafson

Date: _____

5/8/18

Witness Name (printed): _____

Darlene Gustafson

Signature: Z.G. WANG
Zhongguo Wang

Date: 02/14/2018

Witness Signature: [Signature]

Date: 2/14/18

Witness Name (printed): Travis Roe

Witness Signature: [Signature]

Date: 2/14/2018

Witness Name (printed): Fabrizia Venancio

Signature: R. Bruce Diebold
R. Bruce Diebold

Date: 2/15/2018

Witness Signature: [Signature]

Date: 2/15/2018

Witness Name (printed): Vian L. H.

Witness Signature: [Signature]

Date: 2/15/2018

Witness Name (printed): Fabricio Venancio

Signature: S Ashwell
Susan Ashwell

Date: 15 Feb 2018

Witness Signature: [Signature]
Witness Name (printed): Diana Lin

Date: 02/15/2018

Witness Signature: [Signature]
Witness Name (printed): Fabrizio Venancio

Date: 2/15/2018

Signature:

David R. Lancia, Jr.

Date:

2/15/2018

Witness Signature:

Juan L. L.

Date:

2/15/2018

Witness Name (printed):

Juan L. L.

Witness Signature:

Roberto Venancio

Date:

2/15/2018

Witness Name (printed):

Roberto Venancio

Signature: Justin A. Caravella
Justin Andrew Caravella

Date: 4/13/2018

Witness Signature: Nicholas M. Boivier
Witness Name (printed): Nicholas M. Boivier

Date: 4/13/2018

Witness Signature: Travis Tirrell
Witness Name (printed): Travis Tirrell

Date: 4/13/2018

Signature: Wei Lu
Wei Lu

Date: March 9, 2018


Witness Signature: Nicholas M. Boivin
Witness Name (printed): Nicholas M. Boivin

Date: 3/9/2018

Witness Signature: Fabrizio Venancio
Witness Name (printed): Fabrizio Venancio

Date: 3/9/2018

The undersigned (whose title is supplied below) is authorized to act on behalf of:
FORMA Therapeutics, Inc.

Signature:  Date: May 1, 2018
Name (printed): Christine P. Bellon
Title (printed): Senior Vice President

